Emyria Limited (ASX: EMD) says its newly inaugurated Empax Centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics.
The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen known for promoting new nerve cell growth in areas affected by PTSD, depression, and anxiety.
Emyria described its Empax Centre 1 as a “state-of-the-art facility dedicated to the delivery and evaluation of new treatments for mental health”.
The Empax Centre provides infrastructure for the safe administration and evaluation of new medications in both clinical trial and real-world settings.
Emyria said it will receive compensation for facilitating the trial, highlighting its value and expertise in psychological trauma care and clinical trial delivery.
Methylone, identified as TSND-201 by Transcend Therapeutics, is a novel MDMA analogue which has shown promise in rapidly activating neuroplasticity gene expression, including BDNF 2, 3, 4, which is crucial for the recovery processes in neuropsychiatric disorders.
The Phase 2 trial, titled: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD, also referred to as “IMPACT-2” (Investigation of Methylone for Post-Traumatic Stress Disorder [PTSD]) will run in two parts with plans to enrol up to 79 participants across multiple sites in Australia and the United States. Participants enrolled at Empax Center, Emyria will earn fees at market rates for specialist work performed.
EMD was trading 4.3% up at 4.8 cents.